These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 28959705)

  • 1. Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiation.
    Wright K; Winkler MD; Newton BD; Sormani MP; Okuda DT
    Neurol Neuroimmunol Neuroinflamm; 2017 Nov; 4(6):e397. PubMed ID: 28959705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of dimethyl fumarate on lymphocyte subsets.
    Berkovich R; Weiner LP
    Mult Scler Relat Disord; 2015 Jul; 4(4):339-41. PubMed ID: 26195053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations.
    Fox RJ; Chan A; Gold R; Phillips JT; Selmaj K; Chang I; Novas M; Rana J; Marantz JL
    Neurol Clin Pract; 2016 Jun; 6(3):220-229. PubMed ID: 27347439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study.
    Miclea A; Leussink VI; Hartung HP; Gold R; Hoepner R
    J Neurol; 2016 Aug; 263(8):1626-32. PubMed ID: 27260297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis.
    Ghadiri M; Rezk A; Li R; Evans A; Luessi F; Zipp F; Giacomini PS; Antel J; Bar-Or A
    Neurol Neuroimmunol Neuroinflamm; 2017 May; 4(3):e340. PubMed ID: 28377940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
    Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
    Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate.
    Spencer CM; Crabtree-Hartman EC; Lehmann-Horn K; Cree BA; Zamvil SS
    Neurol Neuroimmunol Neuroinflamm; 2015 Jun; 2(3):e76. PubMed ID: 25738172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS.
    Chan A; Rose J; Alvarez E; Bar-Or A; Butzkueven H; Fox RJ; Gold R; Gudesblatt M; Haartsen J; Spelman T; Wright K; Ferraro D; Sola P; Hodgkinson S; Kalincik T; Lechner-Scott J; McGuigan C; Spach K; Chen C; Fam S; Wu F; Miller C
    Neurol Clin Pract; 2020 Dec; 10(6):510-519. PubMed ID: 33510947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
    Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
    Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.
    Kim HT; Armand P; Frederick D; Andler E; Cutler C; Koreth J; Alyea EP; Antin JH; Soiffer RJ; Ritz J; Ho VT
    Biol Blood Marrow Transplant; 2015 May; 21(5):873-80. PubMed ID: 25623931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.
    Zurawski J; Flinn A; Sklover L; Sloane JA
    J Neurol; 2016 Aug; 263(8):1511-7. PubMed ID: 27193310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absolute lymphocyte counts as prognostic indicators for immune thrombocytopenia outcomes in children.
    Deel MD; Kong M; Cross KP; Bertolone SJ
    Pediatr Blood Cancer; 2013 Dec; 60(12):1967-74. PubMed ID: 24038723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of absolute lymphocyte count on day 30 after unmanipulated haploidentical blood and marrow transplantation for pediatric patients with hematological malignancies.
    Chang YJ; Zhao XY; Huo MR; Xu LP; Liu DH; Liu KY; Huang XJ
    Am J Hematol; 2011 Feb; 86(2):227-30. PubMed ID: 21264916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
    Dorman E; Kansal AR; Sarda S
    J Med Econ; 2015; 18(12):1085-91. PubMed ID: 26390149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
    J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should absolute lymphocyte count be used as a surrogate marker for CD4+ count in patients with HIV/AIDS?
    Jibrin YB; Yusuph H; Garbati MA; Gashau W; Abja UM
    Afr J Med Med Sci; 2006 Mar; 35(1):9-13. PubMed ID: 17209321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma.
    Markovic O; Popovic L; Marisavljevic D; Jovanovic D; Filipovic B; Stanisavljevic D; Matovina-Brko G; Hajder J; Matkovic T; Živkovic R; Stanisavljevic N; Todorović M; Petrovic D; Mihaljevic B
    Eur J Intern Med; 2014 Mar; 25(3):296-302. PubMed ID: 24565533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia.
    Sun D; Elson P; Liedtke M; Medeiros BC; Earl M; Alizadeh A; Bates J; Sekeres MA; Coutre S; Kalaycio M; Sobecks R; Copelan E; Advani AS
    Am J Hematol; 2012 Oct; 87(10):957-60. PubMed ID: 22729847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peritransplant absolute lymphocyte count as a predictive factor for advanced recurrence of hepatitis C after liver transplantation.
    Nagai S; Yoshida A; Kohno K; Altshuler D; Nakamura M; Brown KA; Abouljoud MS; Moonka D
    Hepatology; 2014 Jan; 59(1):35-45. PubMed ID: 23728831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.